NextCell Pharma (NXTCL.ST) Stock Price

NextCell Pharma Price

OMX·CLOSED
1.01SEK+0.02 (+1.90 %)
Market closed

Over the last 10 years NextCell Pharma grew revenue by 108.8% annually, reaching 10.94 M SEK. For NextCell Pharma, the net margin of -321.3% is up versus -627.9% a few years ago. The stock trades about 51% above its 52-week low.

NextCell Pharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of NextCell Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how NextCell Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing NextCell Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

NextCell Pharma Stock Price History
DateNextCell Pharma Price
7/24/20261.01 SEK
7/23/20260.99 SEK
7/22/20261.02 SEK
7/21/20261.06 SEK
7/20/20261.04 SEK
7/17/20261.03 SEK
7/16/20261.10 SEK
7/15/20261.08 SEK
7/14/20261.09 SEK
7/13/20261.11 SEK
7/10/20261.18 SEK
7/9/20261.14 SEK
7/8/20261.01 SEK
7/7/20261.00 SEK
7/6/20261.00 SEK
7/3/20260.93 SEK
7/2/20260.97 SEK
7/1/20260.90 SEK
6/30/20260.94 SEK
6/29/20260.99 SEK
6/26/20261.00 SEK
6/25/20261.01 SEK
6/24/20261.01 SEK
6/23/20261.03 SEK
6/22/20261.03 SEK
6/18/20261.05 SEK
6/17/20261.07 SEK
6/16/20261.07 SEK
6/15/20261.05 SEK
6/12/20261.06 SEK
6/11/20261.05 SEK
6/10/20261.10 SEK
6/9/20261.08 SEK
6/8/20261.08 SEK
6/5/20261.11 SEK
6/4/20261.16 SEK
6/3/20261.11 SEK
6/2/20261.13 SEK
6/1/20261.16 SEK
5/29/20261.25 SEK
5/28/20261.23 SEK
5/27/20261.28 SEK
5/26/20261.28 SEK
5/25/20261.27 SEK
5/22/20261.14 SEK
5/21/20261.13 SEK
5/20/20261.17 SEK
5/19/20261.10 SEK
5/18/20261.06 SEK
5/15/20261.09 SEK
5/13/20261.08 SEK
5/12/20261.16 SEK
5/11/20261.24 SEK
5/8/20261.23 SEK
5/7/20261.24 SEK
5/6/20261.20 SEK
5/5/20261.12 SEK
5/4/20261.05 SEK
4/30/20261.10 SEK
4/29/20261.15 SEK
4/28/20261.16 SEK
4/27/20261.19 SEK
4/24/20261.17 SEK
4/23/20261.18 SEK
4/22/20261.20 SEK
4/21/20261.22 SEK
4/20/20261.21 SEK
4/17/20261.31 SEK
4/16/20261.36 SEK
4/15/20261.42 SEK
4/14/20261.31 SEK
4/13/20261.31 SEK
4/10/20261.38 SEK
4/9/20261.33 SEK
4/8/20261.30 SEK
4/7/20261.25 SEK
4/2/20261.21 SEK
4/1/20261.20 SEK
3/31/20261.24 SEK
3/30/20261.26 SEK
3/27/20261.27 SEK
3/26/20261.30 SEK
3/25/20261.30 SEK
3/24/20261.29 SEK
3/23/20261.27 SEK
3/20/20261.20 SEK
3/19/20261.21 SEK
3/18/20261.29 SEK
3/17/20261.21 SEK
3/16/20261.22 SEK
3/13/20261.30 SEK
3/12/20261.28 SEK
3/11/20261.28 SEK
3/10/20261.28 SEK
3/9/20261.27 SEK
3/6/20261.33 SEK
3/5/20261.29 SEK
3/4/20261.30 SEK
3/3/20261.30 SEK
3/2/20261.35 SEK
2/27/20261.41 SEK
2/26/20261.38 SEK
2/25/20261.48 SEK
2/24/20261.52 SEK
2/23/20261.53 SEK
2/20/20261.54 SEK
2/19/20261.58 SEK
2/18/20261.55 SEK
2/17/20261.41 SEK
2/16/20261.37 SEK
2/13/20261.44 SEK
2/12/20261.42 SEK
2/11/20261.49 SEK
2/10/20261.50 SEK
2/9/20261.57 SEK
2/6/20261.59 SEK
2/5/20261.56 SEK
2/4/20261.69 SEK
2/3/20261.64 SEK
2/2/20261.35 SEK
1/30/20261.30 SEK
1/29/20261.33 SEK
1/28/20261.26 SEK
1/27/20261.29 SEK
1/26/20261.21 SEK
1/23/20261.37 SEK
1/22/20261.49 SEK
1/21/20261.45 SEK
1/20/20261.65 SEK
1/19/20261.18 SEK
1/16/20261.28 SEK
1/15/20260.89 SEK
1/14/20260.74 SEK
1/13/20260.78 SEK
1/12/20260.73 SEK
1/9/20260.69 SEK
1/8/20260.68 SEK
1/7/20260.70 SEK
1/5/20260.70 SEK
1/2/20260.70 SEK
12/30/20250.73 SEK
12/29/20250.69 SEK
12/23/20250.70 SEK
12/22/20250.70 SEK
12/19/20250.67 SEK
12/18/20250.68 SEK
12/17/20250.69 SEK
12/16/20250.69 SEK
12/15/20250.68 SEK
12/12/20250.68 SEK
12/11/20250.70 SEK
12/10/20250.71 SEK
12/9/20250.68 SEK
12/8/20250.70 SEK
12/5/20250.74 SEK
12/4/20250.74 SEK
12/3/20250.78 SEK
12/2/20250.74 SEK
12/1/20250.76 SEK
11/28/20250.77 SEK
11/27/20250.67 SEK
11/26/20250.71 SEK
11/25/20250.74 SEK
11/24/20250.75 SEK
11/21/20250.80 SEK
11/20/20250.82 SEK
11/19/20250.84 SEK
11/18/20250.79 SEK
11/17/20250.80 SEK
11/14/20250.79 SEK
11/13/20250.80 SEK
11/12/20250.74 SEK
11/11/20250.77 SEK
11/10/20250.81 SEK
11/7/20250.82 SEK
11/6/20250.85 SEK
11/5/20250.84 SEK
11/4/20250.86 SEK
11/3/20250.89 SEK
10/31/20250.90 SEK
10/30/20250.90 SEK
10/29/20250.89 SEK
10/28/20250.89 SEK
10/27/20250.88 SEK
10/24/20250.93 SEK
10/23/20250.93 SEK
10/22/20250.95 SEK
10/21/20250.93 SEK
10/20/20250.92 SEK
10/17/20250.92 SEK
10/16/20250.89 SEK
10/15/20250.90 SEK
10/14/20250.90 SEK
10/13/20250.92 SEK
10/10/20250.93 SEK
10/9/20250.94 SEK
10/8/20250.95 SEK
10/7/20250.94 SEK
10/6/20250.95 SEK
10/3/20250.98 SEK
10/2/20250.98 SEK
10/1/20250.97 SEK
9/30/20250.95 SEK
9/29/20250.93 SEK
9/26/20250.96 SEK
9/25/20250.97 SEK
9/24/20250.99 SEK
9/23/20250.99 SEK
9/22/20251.01 SEK
9/19/20251.00 SEK
9/18/20251.01 SEK
9/17/20251.02 SEK
9/16/20251.02 SEK
9/15/20251.05 SEK
9/12/20251.07 SEK
9/11/20251.03 SEK
9/10/20251.04 SEK
9/9/20251.08 SEK
9/8/20251.11 SEK
9/5/20251.08 SEK
9/4/20251.13 SEK
9/3/20251.18 SEK
9/2/20251.16 SEK
9/1/20251.18 SEK
8/29/20251.17 SEK
8/28/20251.18 SEK
8/27/20251.14 SEK
8/26/20251.14 SEK
8/25/20251.14 SEK
8/22/20251.15 SEK
8/21/20251.15 SEK
8/20/20251.18 SEK
8/19/20251.19 SEK
8/18/20251.17 SEK
8/15/20251.17 SEK
8/14/20251.19 SEK
8/13/20251.17 SEK
8/12/20251.20 SEK
8/11/20251.21 SEK
8/8/20251.21 SEK
8/7/20251.20 SEK
8/6/20251.19 SEK
8/5/20251.19 SEK
8/4/20251.17 SEK
8/1/20251.17 SEK
7/31/20251.19 SEK
7/30/20251.17 SEK
7/29/20251.20 SEK
7/28/20251.27 SEK
Access this data via the Eulerpool API
Get Free API Key

NextCell Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
3.56 M SEK
-17.70 M SEK
-17.69 M SEK
Jan 1, 2021
3.91 M SEK
-24.82 M SEK
-24.56 M SEK
Jan 1, 2022
5.59 M SEK
-35.02 M SEK
-34.08 M SEK
Jan 1, 2023
10.11 M SEK
-41.00 M SEK
-39.81 M SEK
Jan 1, 2024
10.66 M SEK
-43.17 M SEK
-41.96 M SEK
Jan 1, 2025
10.94 M SEK
-35.87 M SEK
-35.14 M SEK
Jan 1, 2026 (e)
0.00 SEK
-55.40 M SEK
-44.56 M SEK
Jan 1, 2027 (e)
254.40 M SEK
235.94 M SEK
-44.56 M SEK

NextCell Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 27, 2026, 8:28 PM
 
REVENUEM SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e
––––1.003.003.005.0010.0010.0010.00–254.00
–––––200.00–66.67100.00––––
––––-1,400.00-333.33-466.67-440.00-350.00-40.00-350.00–-350.00
-5.00-5.00-2.00-8.00-14.00-10.00-14.00-22.00-35.00-4.00-35.00-35.00-889.00
-10.00-11.00-13.00-14.00-21.00-17.00-24.00-35.00-41.00-43.00-35.00-55.00235.00
––––-2,100.00-566.67-800.00-700.00-410.00-430.00-350.00–92.52
-10.00-11.00-13.00-14.00-21.00-17.00-24.00-34.00-39.00-41.00-35.00-44.00-44.00
–10.0018.187.6950.00-19.0541.1841.6714.715.13-14.6325.71–
10.955.2517.0121.3938.2946.8068.7668.7668.7673.09111.39111.39111.39
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales NextCell Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue NextCell Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare NextCell Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares NextCell Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against NextCell Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

NextCell Pharma stock margins

The NextCell Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NextCell Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NextCell Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-291.00 %
-496.60 %
-496.24 %
Jan 1, 2021
-371.36 %
-634.48 %
-627.92 %
Jan 1, 2022
-398.31 %
-626.68 %
-609.88 %
Jan 1, 2023
-8.75 %
-405.42 %
-393.65 %
Jan 1, 2024
-42.74 %
-404.81 %
-393.45 %
Jan 1, 2025
-327.98 %
-327.98 %
-321.31 %
Jan 1, 2026 (e)
-327.98 %
- %
- %
Jan 1, 2027 (e)
-327.98 %
92.74 %
-17.51 %

NextCell Pharma Stock Revenue, EBIT, Earnings per Share

The NextCell Pharma earnings per share therefore indicates how much revenue NextCell Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.08 SEK
-0.38 SEK
-0.38 SEK
Jan 1, 2021
0.06 SEK
-0.36 SEK
-0.36 SEK
Jan 1, 2022
0.08 SEK
-0.51 SEK
-0.50 SEK
Jan 1, 2023
0.15 SEK
-0.60 SEK
-0.58 SEK
Jan 1, 2024
0.15 SEK
-0.59 SEK
-0.57 SEK
Jan 1, 2025
0.10 SEK
-0.32 SEK
-0.32 SEK
Jan 1, 2026 (e)
0.00 SEK
-0.50 SEK
-0.40 SEK
Jan 1, 2027 (e)
2.28 SEK
2.12 SEK
-0.40 SEK

NextCell Pharma business model & stock analysis

NextCell Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

NextCell Pharma historical P/E ratio, EBIT multiple, and P/S ratio

NextCell Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

NextCell Pharma shares outstanding

The number of shares of NextCell Pharma was 111.39 M in 2025. This indicates how many shares NextCell Pharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
46.80 M Stocks
Jan 1, 2021
68.76 M Stocks
Jan 1, 2022
68.76 M Stocks
Jan 1, 2023
68.76 M Stocks
Jan 1, 2024
73.09 M Stocks
Jan 1, 2025
111.39 M Stocks
Jan 1, 2026 (e)
111.39 M Stocks
Jan 1, 2027 (e)
111.39 M Stocks
Price targets and forecasts for NextCell Pharma are not yet available.

NextCell Pharma shareholder structure

% Name
9.76318%
Avanza Bank Holding AB
Avanza Bank Holding AB
4.51637%
Mertiva AB
Mertiva AB
2.54833%
Ålandsbanken Sverige AB
Ålandsbanken Sverige AB
1.59767%
Pabros AB
Pabros AB
1.58674%
Nordnet Pensionsforsakring AB
Nordnet Pensionsforsakring AB
1.43639%
Larsen (Martin)
Larsen (Martin)

NextCell Pharma Executives and Management Board

AE

Anders Essen-Möller

(81)

Chairman · since 2014

MP

Mathias Svahn, PhD

(46)

Chief Executive Officer · since 2014

SF

Sofia Fredrikson

(39)

Chief Financial Officer · since 2018

LP

Lindsay Davies, PhD

(43)

Chief Scientific Officer · since 2020

EP

Edvard Smith, MD, PhD

(71)

Director & Medical Manager · since 2014

Frequently asked questions about NextCell Pharma

Converted at the current exchange rate, the NextCell Pharma share trades at 0.09 EUR (1.01 SEK).

All fundamentals and in-depth analysis of NextCell Pharma

Our stock analysis for NextCell Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NextCell Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

NextCell Pharma Stock
NextCell Pharma Revenue→
NextCell Pharma Stock
NextCell Pharma Net Income→
NextCell Pharma Stock
NextCell Pharma P/E→
NextCell Pharma Stock
NextCell Pharma P/S→
NextCell Pharma Stock
NextCell Pharma EBIT→
NextCell Pharma Stock
NextCell Pharma Dividend→
NextCell Pharma Stock
NextCell Pharma Directors Dealings→
NextCell Pharma Stock
NextCell Pharma Stocks→
NextCell Pharma Stock
NextCell Pharma Market capitalization→
NextCell Pharma Stock
NextCell Pharma Debt→
NextCell Pharma Stock
NextCell Pharma Liabilities→
NextCell Pharma Stock
NextCell Pharma Equity→
NextCell Pharma Stock
NextCell Pharma AAQS→
NextCell Pharma Stock
NextCell Pharma Employees→
NextCell Pharma Stock
NextCell Pharma ROE→
NextCell Pharma Stock
NextCell Pharma ROA→
NextCell Pharma Stock
NextCell Pharma ROCE→
NextCell Pharma Stock
NextCell Pharma News→
NextCell Pharma Stock
NextCell Pharma Analyst Price Targets→

Health Stocks

NextCureNextBioMedical CoNextleaf SolutionsNexstim OyjNfl Biosciences SASNeximmuneNGeneBio CoNexien BiopharmaNgl Fine ChemNexgelNGS GroupNexalin TechnologyAll Stocks A–Z →